Quality Verification of Dendritic Cell-Based Cancer Vaccine
Quality Verification of Dendritic Cell-Based Cancer Vaccine
复制标题
基于树突状细胞的癌症疫苗的质量验证
DOI：
10.4172/2153-2435.1000465
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
S. Koido
中科院分区：
文献类型：
--
作者：
S. Shimodaira;Terutsugu Koya;Y. Higuchi;M. Okamoto;S. Koido
在个人化癌症治疗的时代，免疫治疗现在正在成为一种潜在的选择。治疗性肿瘤疫苗已被开发用于诱导针对肿瘤相关抗原的有效免疫反应。基于树突状细胞(DC)的疫苗的有效性归因于它们诱导抗癌免疫的能力。批准治疗活性DC的标准，例如它们的活性和纯度，在这里是基于表型特征，与它们的抗原提呈能力以及吞噬和吞噬作用的功能分析相联系。具有生物活性功能的标准化DC表型将有助于为癌症免疫治疗提供个性化疫苗。
In the era of personalized cancer therapy, immunotherapy is now emerging as a potential option. Therapeutic cancer vaccination has been developed for the induction of an efficient immune response targeting tumor-associated antigens. The efficacy of dendritic cell (DC)-based vaccines is attributed to their ability to induce immunity against cancers. Criteria for the approval of therapeutically active DCs, such as their viability and purity, are here verified based on phenotypic characteristics, linked to their antigen-presenting ability and functional analyses of phagocytosis and pinocytosis. A standardized phenotype of DCs harboring bioactive functions would be useful to provide personalized vaccines for cancer immunotherapy.
疫苗、佐剂和树突状细胞激活剂——现状和未来的挑战。
影响因子：
4
作者：
Obeid,Joseph;Hu,Yinin;SlingluffJr,CraigL
通讯作者：
SlingluffJr,CraigL